PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
PureTech Health announced that Phase 1b results for LYT-200, a first-in-class anti-galectin-9 antibody, will be presented orally at the ESMO Congress 2026 on October 24 in Madrid. The company describes the data in heavily pretreated relapsed/refractory high-risk MDS and AML patients as showing encouraging clinical activity with a favorable safety profile, though no specific figures are disclosed in this release. Founded Entity Gallop Oncology, wholly owned by PureTech, plans to advance LYT-200 into the Phase 2 STRIDE-MDS trial following a successful FDA End-of-Phase 1 meeting; the asset already holds Fast Track designations for R/R HR-MDS and AML.
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Seaport Therapeutics presented the first scientific data from its GlyphAgo Phase 1 program at the ECNP Congress in Munich, showing a statistically significant 6.8-fold increase in agomelatine bioavailability and roughly 10-fold lower PK variability versus unmodified agomelatine. The multi-part trial in 174 healthy volunteers showed dose-dependent exposure, no food effect, and no accumulation over seven days of dosing, with the Glyphed prodrug designed to bypass first-pass liver metabolism and reduce liver enzyme risk. Seaport has initiated a Phase 2a trial of GlyphAgo in generalized anxiety disorder with sleep disturbance (topline early 2028) and plans a Phase 2/3 GAD trial starting in the first half of 2027. PureTech Health, the founding hub company, noted the announcement.
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Seaport Therapeutics dosed the first patient in a six-week Phase 2a trial in Australia evaluating GlyphAgo (SPT-320) in adults with generalized anxiety disorder and sleep disturbance. The trial is designed as proof-of-pharmacology, measuring effects on sleep via the Insomnia Severity Index and EEG-based sleep-architecture measures, with topline data expected in early 2028. Phase 1 data showed a statistically significant 6.8-fold bioavailability increase versus unmodified agomelatine with no liver-related adverse events; a global Phase 2/3 GAD trial is planned for the first half of 2027 with topline data by end of 2028. PureTech Health (LSE: PRTC), Seaport's founding hub, noted the announcement as part of its hub-and-spoke model.
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
PureTech Health (LSE: PRTC) announced a successful End-of-Phase 1 meeting with the FDA and receipt of Fast Track designation for LYT-200 in combination with a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes. The FDA feedback supports advancement into the Phase 2 STRIDE-MDS trial, a randomized, double-blind, placebo-controlled study of approximately 125 patients comparing 12 mg/kg and 7.5 mg/kg doses of LYT-200 plus an HMA against placebo plus an HMA. In the completed Phase 1b, LYT-200 plus an HMA produced a 45.5% overall response rate and 27.3% complete response rate in 11 efficacy-evaluable patients with no dose-limiting toxicities, against a literature benchmark of fewer than 5% responding to HMA rechallenge. PureTech intends to secure external capital in the first half of 2027 through its wholly owned Founded Entity, Gallop Oncology, to fund LYT-200 through completion of the Phase 2 trial.
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Seaport Therapeutics (Nasdaq: SPTX) reported positive topline results from its Phase 1 Driving Simulation Trial of GlyphAllo (SPT-300), with the primary endpoint met — evening dosing at 375 mg, the highest dose in the Phase 2b BUOY-1 trial, did not impair next-morning driving performance versus placebo on Day 5 after multiple-day dosing. The key secondary endpoint was also met, with a single 250 mg evening dose showing no next-morning driving impairment on Day 2. A 7.5 mg zopiclone positive control produced statistically significant impairment, confirming assay sensitivity, and GlyphAllo was well tolerated with no serious adverse events. Seaport plans to submit the results to the FDA as part of GlyphAllo's development program for major depressive disorder. The potentially registration-enabling Phase 2b BUOY-1 trial is actively enrolling, with topline data expected in the first half of 2027. PureTech Health (LSE: PRTC), Seaport's founding entity, noted the announcement; the data reinforce GlyphAllo's differentiation profile — benefits of allopregnanolone without next-morning driving effects — ahead of the pivotal readout.
PureTech Health: Notice of Half-Yearly Results
PureTech Health plc (LSE: PRTC) plans to announce its half-yearly results for the six months ended 30 June 2026 on Tuesday 22 September 2026. A presentation and conference call will be held at 9:00 a.m. BST on the day of publication, with a webcast available on the company's investor relations website. PureTech is a hub-and-spoke biotherapeutics company whose capital-efficient R&D model has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval.
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
PureTech Health's founded entity Celea Therapeutics announced it will present two abstracts on its investigational therapy deupirfenidone at the European Respiratory Society Congress in Barcelona. The presentations will detail the design of SURPASS-IPF, a global Phase 3 head-to-head trial comparing deupirfenidone 825 mg TID against pirfenidone 801 mg TID in approximately 1,100 adults with idiopathic pulmonary fibrosis. Additionally, Celea will share Phase 1 data indicating that clinically relevant drug-drug interactions are unlikely when deupirfenidone is co-administered with nintedanib.
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress
Celea Therapeutics, founded by PureTech Health, announced it will present the Phase 3 design for SURPASS-IPF and Phase 1 drug-drug interaction data at the ERS Congress. The global head-to-head SURPASS-IPF trial will enroll approximately 1,100 adults to evaluate the superiority of deupirfenidone 825 mg TID versus pirfenidone 801 mg TID over 52 weeks. Phase 1 data indicate that clinically relevant drug-drug interactions are unlikely with co-administration of deupirfenidone and nintedanib.
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
PureTech Health plc announced that its Founded Entity, Celea Therapeutics, has dosed the first patient in the global Phase 3 SURPASS-IPF trial evaluating deupirfenidone for idiopathic pulmonary fibrosis (IPF). The head-to-head trial will compare deupirfenidone 825 mg TID against pirfenidone 801 mg TID in approximately 1,100 patients over 52 weeks, with topline data expected in the second half of 2029. This clinical milestone follows Celea's recent $180 million financing, which supports the continued advancement of the program toward potential registration.
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
PureTech Health's (PRTC) founded entity, Celea Therapeutics, closed a $180 million financing with top-tier investors including RA Capital Management and Leaps by Bayer. Proceeds will fund the early Q3 2026 initiation of the SURPASS-IPF Phase 3 trial, which is the first head-to-head study evaluating deupirfenidone's superiority over current standard-of-care pirfenidone. This capital raise significantly de-risks the advancement of PureTech's lead respiratory asset without requiring substantial additional funding from the parent company.
PureTech Health: Results of Annual General Meeting
PureTech Health held its Annual General Meeting on June 10, 2026, where all 15 proposed resolutions were passed by shareholders on a poll. The board was reconstituted with the re-election of Sharon Barber-Lui, Michele Holcomb, John LaMattina, Robert Langer, and Kiran Mazumdar-Shaw, alongside the election of Robert Lyne. Shareholders also approved the annual report, auditor reappointment, and authorized share allotment and buyback powers, with voting support ranging from 82% to 99.9% across resolutions.
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
PureTech Health will showcase its deupirfenidone (LYT-100) program at the American Thoracic Society International Conference, highlighting its potential as a new standard of care for idiopathic pulmonary fibrosis (IPF). The SURPASS-IPF Phase 3 trial is designed to test deupirfenidone against the current standard of care, pirfenidone, with a head-to-head superiority design. This trial builds on the positive Phase 2b ELEVATE IPF results, which demonstrated the potential to stabilize lung function decline while maintaining a favorable safety profile. PureTech’s Senior Vice President of Medical Affairs, Camilla Graham, MD, MPH, emphasized the unmet need for enhanced efficacy in IPF treatment and the strategic use of advanced imaging technologies to better characterize disease severity.
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
PureTech Health intends to voluntarily delist its American Depositary Shares from Nasdaq to concentrate trading on the London Stock Exchange, which will serve as its primary venue. The Board determined that the dual listing is no longer necessary given that the substantial majority of trading volume, liquidity, and investors are based in the UK. The company expects to file a Form 15F to deregister and suspend SEC reporting obligations, with ADSs moving to the over-the-counter market.
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
PureTech Health plc announced that its founded entity, Seaport Therapeutics, appointed Dr. Sharon Mates to its board of directors. Dr. Mates previously served as CEO of Intra-Cellular Therapies, leading the company through its $14.6 billion acquisition by Johnson & Johnson in 2025. The release notes Dr. Mates currently sits on the board of Benitec (BNTC), though the appointment pertains exclusively to Seaport Therapeutics.
PureTech Health: Notice of Results
